Howard Scher

14PUBLICATIONS
198CO-AUTHORS
Molecular targetsRadiation therapyNatural language processingClinical chemistry (incl. diagnostics)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 09, 2026
Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

|Jun 15, 2026
Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

|Feb 19, 2026
Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study.

Sean M McBride, Daniel E Spratt, Marisa Kollmeier

|Nov 20, 2025
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.

Deaglan McHugh, Matthew Dallos, Min Yuen Teo

|Nov 07, 2024
Automated real-world data integration improves cancer outcome prediction.

Justin Jee, Christopher Fong, Karl Pichotta

|Sep 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann

Pageof 3

Frequent Collaborators

4 joint publications

Michael Morris

3 joint publications

Dana Rathkopf

3 joint publications

Jeremie Calais

3 joint publications

Karen A Autio